AviadoBio

AviadoBio

Private
London, EnglandHealthcare & Life Scienceshttps://www.aviadobio.com

Last Round

Corporate Funding

Oct 8, 2024

Total Funding Raised

$116.5M

Company Overview

AviadoBio is a biotechnology company that develops innovative gene therapies aimed at transforming the lives of individuals affected by severe neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyAAV gene therapyfrontotemporal dementiaFTDneurodegenerative disordersamyotrophic lateral sclerosisALSAAV platformone-time therapyCNS gene therapydisease-modifying therapyLou Gehrig's diseaseclinical-stage biotechintrathecal deliverybiopharma licensingoptogeneticsretinal disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AviadoBio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AviadoBio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingOct 8, 2024
Series ADec 2, 2021
SeedApr 1, 2021

Key People

Founding team and executive leadership

Lisa Deschamps

Chief Executive Officer Board Member

Executive Team

Graeme Fielder

Chief Operating Officer

Executive Team

AviadoBio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Combining RNAi platform with TfR1 capsid for CNS gene silencing.

  • Apr 27, 2026

    Presenting drug candidate data at the ASGCT Annual Meeting.

AviadoBio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AviadoBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AviadoBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon, England
Employee Range71
Year Founded2019
Last FundingOct 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.